PTO/SB/21 (09-06) Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE vork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/751.380 TRANSMITTAL Filing Date 01/05/2004 **FORM** First Named Inventor Zahner, Joseph E. Art Unit 1636 **Examiner Name** Schlapkohl, Walter (to be used for all correspondence after initial filing) Attorney Docket Number NR 04-001 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Return receipt postcard. Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Joseph E. Zafine Signature Printed name Joseph E. Zahner Date Reg. No. October 12, 2006 pro se

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mair in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date October 12, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Date October 12, 2006

Docket No. NR 04-001

CERTIFICATION UNDER 37 CFR 1.8

I hereby certify that this correspondendce is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 12, 2006

Joseph E. Zahner

(Typed name of person mailing paper)

(Signature of person mailing paper)

Transmitted herewith for filing is an amendment and related papers for:

Application of: Joseph E. Zahner

Art Unit:

1636

Serial No.:

10/751,380

Atty. Docket No.: NR 04-001

Filed:

01/05/2004

For:

Inhibitor of Cell Proliferation and

Examiner:

Walter Schlapkohl

Methods of Use Thereof

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO NON-FINAL OFFICE ACTION

In response to the Official Action, which was mailed on July 13, 2006, Applicant submits the following amendment to the specification and claims. Applicant believes that the amendment places the case in a condition for allowance and respectfully requests that the claims be allowed.

Sequence Compliance. Examiner contends that the application fails to comply with 37 CFR 1.821 -1.825 due to the lack of a statement that the computer readable form of the sequence listing is the same as the paper copy submitted with the application.

Applicant respectfully points out that paragraph [0002] of the application-as-filed makes such a statement. For clarity sake, Applicant restates that statement here:

> A paper copy of the sequence listing and a computer readable form of the same sequence listing submitted with the application-as-filed and therein

incorporated by reference. The information recorded in computer readable form is identical to the written sequence listing, according to 37 C.F.R. 1.821 (f).

Specification. The disclosure is objected to for failing to reflect that the instant case is in fact a continuation of patent no. 6,673,894. Applicant respectfully requests that paragraph [0001] be amended, as set forth below.

Claim Objections. Claims 9 and 12 are objected to for containing non-elected subject matter. Applicant has amended claim 9 to remove "a cell in a transgenic animal" and has amended claim 12 to remove the reference to SEQ IN NO:25, as set forth below. Claim 13 is also objected to for being dependent upon a base claim containing non-elected subject matter. Claim 13 is dependent upon claim 12, which has been amended to be directed to elected subject matter only. The amendment to claim 12 renders the objection to claim 13 moot.

Allowable Subject Matter. Applicant thanks Examiner for allowing claims 6-8, 10 and 11.

If any other issues remain pertaining to this office action and response, Examiner is invited to contact undersigned Inventor.

Respectfully submitted,

Joseph E. Zahner

3646 Doyer Place

St. Louis, MO 63116

(314) 977-7731, FAX (314) 977-1008